Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KRAS | P01116 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989475 | 1.00 | KMT2A (0.51) | KMT2APOLBMEN1KRASMMP1 | |
| SCHEMBL10144975 | 0.87 | MMP1 (0.47) | KMT2AMEN1KRASMMP1PTGS2 | |
| SCHEMBL4982840 | 0.86 | MAPT (0.57) | KMT2AMEN1KRASMMP1PTGS2 | |
| SCHEMBL4982850 | 0.86 | MAPT (0.57) | KMT2AMEN1KRASMMP1PTGS2 | |
| SCHEMBL4985532 | 0.79 | MAPT (0.54) | KMT2APOLBMEN1MAPTALDH1A1 | |
| SCHEMBL15367534 | 0.75 | MAOB (0.61) | KMT2APOLBMEN1PTGS2MAOB | |
| SCHEMBL17355377 | 0.75 | MAOB (0.61) | KMT2APOLBMEN1PTGS2MAOB | |
| SCHEMBL5315888 | 0.75 | MAOB (0.61) | KMT2APOLBMEN1PTGS2MAOB | |
| SCHEMBL9523424 | 0.75 | MAOB (0.61) | KMT2APOLBMEN1PTGS2MAOB | |
| SCHEMBL522693 | 0.72 | CA12 (0.62) | KMT2AMEN1KRASPTGS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8192717-B2 | Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening | NAGASAKI UNIVERSITY (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | Mori, Hiroshi (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1815872-A1 | COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS | Nagasaki University (JP) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815872-A1 | COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS | Nagasaki University (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | APP, APBA1, FABP7 | KMT2A 4676/4885POLB 4169/4885MEN1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.